Interleukin-6 as a predictor of cardiovascular events in troponin-negative non-ST elevation acute coronary syndrome patients

García-Salas, José María; Tello‐Montoliu, Antonio; Manzano‐Fernández, Sergio; Casas-Pina, Teresa; Pérez-Berbel, Patricio; Puche-Morenilla, Carmen María; Martı́nez-Hernández, Pedro; Valdés, Mariano; Marı́n, Francisco

doi:10.1111/ijcp.12245

Cited by 16 publications

(13 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this process, inflammation is thought to play a key role along with several other risk factors 33 . Previous investigations have shown that a high level of IL-6 is an independent predictor of adverse events in patients with ACS 34 . Our data showed that the presence of the D allele is related to higher IL-6, with 18.6 ng/ml in DD and 18.0 ng/ml in ID versus 14.7 ng/ml with the II genotype 15 .…”

Section: Discussionmentioning

confidence: 93%

Associations of ACE I/D polymorphism with the levels of ACE, kallikrein, angiotensin II and interleukin-6 in STEMI patients

Dai

Ding

Liang³

et al. 2019

Sci Rep

View full text Add to dashboard Cite

This study aimed to compare the plasma levels of angiotensin-I converting enzyme (ACE), Angiotensin II (AngII), kallikrein (KLK1) and interleukin-6 (IL-6) in ST segment elevation myocardial infarction (STEMI) patients with different ACE Insertion/deletion (I/D) polymorphisms in a Chinese population. The ACE genotypes were determined in the 199 STEMI patients and 216 control subjects. STEMI patients were divided into three groups based on the ACE genotypes. Single polymerase chain reaction (PCR) was performed to characterize ACE I/D polymorphisms. Plasma levels of ACE, AngII, KLK1 and IL-6 were measured by enzyme-linked immunosorbent assay (ELISA). We found that the DD or ID genotype was significantly independently associated with high ACE (OR = 4.697; 95% CI = 1.927–11.339), KLK1 (3.339; 1.383–8.063) and IL-6 levels (OR = 2.10; 1.025–4.327) in STEMI patients. However, there was no statistical significance between the ACE I/D polymorphism and AngII plasma levels whether in univariate or multivariate logistic regression. Additionally, we detected a significantly positive correlation between plasma KLK1 levels and IL-6 levels in STEMI patients (r = 0.584, P < 0.001). The study showed high levels of ACE, KLK1 and IL-6 were detected when the D allele was present, but AngII plasma levels was not influenced by the ACE I/D polymorphism.

show abstract

Section: Discussionmentioning

confidence: 93%

Associations of ACE I/D polymorphism with the levels of ACE, kallikrein, angiotensin II and interleukin-6 in STEMI patients

Dai

Ding

Liang³

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Wang et al 55 found that IL-6 was related to the procession of ACS and had prognostic use. Serum IL-6 was shown to be useful for predicting mortality in patients with ACS51 and identifying individuals who could benefit from targeted interventional or intensive therapy 56. However, the circadian fluctuation in IL-6 levels and a lack of confirmatory studies have limited the use of IL-6 as an effective biomarker of ACS 57.…”

Section: Summary Of Cardiac Biomarkersmentioning

confidence: 99%

Diagnostic and prognostic value of biomarkers in acute myocardial infarction

Chen

Tao

Zhang

et al. 2019

Postgraduate Medical Journal

View full text Add to dashboard Cite

The incidence of acute myocardial infarction (AMI) has been increasing rapidly in recent years, seriously endangering human health. Cardiac biomarkers play critical roles in the diagnosis and prognosis of AMI. Troponin is a highly sensitive and specific biomarker for AMI diagnosis and can independently predict adverse cardiac events. Other biomarkers such as N-terminal B-type natriuretic peptide and C reactive protein are also valuable predictors of cardiovascular prognosis. Recently, several novel biomarkers have been identified for the diagnosis and risk assessment in patients with AMI. A multibiomarker approach can potentially enhance the diagnostic accuracy and provide more information for the early risk stratification of AMI. In this review, we will summarise the biomarkers discovered in recent years and focus on their diagnostic and prognostic value for patients with AMI.

show abstract

“…Inflammation plays an important role in the progression and destabilisation of ACS. Several inflammatory biomarkers, such as interleukin-6 [2], C-reactive protein [3], and matrix metalloproteinases [4], have been identified as independent predictors of adverse outcomes in patients with ACS. However, these biomarkers are not used as routine or inexpensive examinations for patients with ACS.…”

Section: Introductionmentioning

confidence: 99%

The prognostic value of the platelet-to-lymphocyte ratio in acute coronary syndrome: a systematic review and meta-analysis

Li¹,

Zhou²,

Ma³

et al. 2017

Kardiol Pol

View full text Add to dashboard Cite

show abstract

Interleukin-6 as a predictor of cardiovascular events in troponin-negative non-ST elevation acute coronary syndrome patients

Cited by 16 publications

References 39 publications

Associations of ACE I/D polymorphism with the levels of ACE, kallikrein, angiotensin II and interleukin-6 in STEMI patients

Associations of ACE I/D polymorphism with the levels of ACE, kallikrein, angiotensin II and interleukin-6 in STEMI patients

Diagnostic and prognostic value of biomarkers in acute myocardial infarction

The prognostic value of the platelet-to-lymphocyte ratio in acute coronary syndrome: a systematic review and meta-analysis

Contact Info

Product

Resources

About